The target antigens commonly used in the CAR constructs include CD19, CD7, CD123, and CD33 to target primary leukemia cells and lymphoma cells [77,78], EGFR and human epidermal growth factor receptor 2 (HER2) to target glioblastoma cells and gynecologic cancers [79,80], MUCI to target solid tumors [41], ROBO1 for pancreatic cancer [41], CD5 to target malignant T-cells [81], FLT-3 to target leukemia cells harboring this mutation [82], and mesothelin to target ovarian cancer cells [83]; several phase I/II trials are currently underway [77]. This evidence concerns the gene ERBB2 and lymphoma.